Mirtazapine Can Cause Mania, But the Risk is Low
Yes, mirtazapine can precipitate mania or hypomania, particularly in patients with bipolar disorder, though the absolute risk is low at 0.2% in controlled trials. The FDA drug label explicitly warns about this risk and mandates screening for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment 1.
Understanding the Risk Profile
The FDA-approved labeling for mirtazapine clearly states that treating a depressive episode with mirtazapine in patients with bipolar disorder may precipitate a mixed/manic episode 1. In controlled clinical trials where bipolar patients were generally excluded, symptoms of mania or hypomania occurred in 0.2% of mirtazapine-treated patients 1.
Key Risk Factors for Manic Switch:
- Bipolar disorder diagnosis (especially if unrecognized)
- Personal or family history of mania/hypomania
- Mixed depressive features (dysphoria, irritability, agitation)
- Higher doses (antidepressant range: 15-45 mg)
- Abrupt medication changes or drug interactions
- Absence of mood stabilizer co-therapy
Clinical Context and Dose-Dependent Risk
The risk of manic switch appears strongly dose-dependent. A 2015 systematic review found that low doses of mirtazapine used for hypnotic/sedative effects (typically 7.5-15 mg) caused mania only in patients with other risk factors for switching 2. When used at antidepressant doses (30-45 mg) without mood stabilizer co-therapy, the risk increases substantially 2.
When combined with mood stabilizers, mirtazapine appears relatively safe even at antidepressant doses, with sparse evidence of increased switching risk 2. This aligns with guideline recommendations that antidepressants in bipolar depression should always be combined with mood stabilizers (lithium or valproate), with SSRIs preferred over tricyclics 3.
Distinguishing Mania from Behavioral Activation:
The FDA label notes that behavioral activation (restlessness, insomnia, impulsiveness, disinhibition) may occur early in SSRI treatment but applies this caution broadly to antidepressants 4. True mania typically appears later in treatment and persists after dose reduction, whereas behavioral activation improves quickly with dose decrease or discontinuation 4.
Mechanism and Clinical Presentations
Case reports suggest mirtazapine-induced mania may involve a noradrenergic syndrome characterized by dysphoria, irritability, insomnia, and psychomotor agitation, related to mirtazapine's blockade of α2-presynaptic adrenergic receptors 5. Notably, manic episodes have been reported both during treatment initiation 5, 6 and following abrupt withdrawal 7, 8.
Withdrawal-Induced Mania:
Mirtazapine withdrawal can also precipitate mania, though this is rarely reported 7, 8. One autopsy-confirmed case documented a fatal manic episode occurring 4 days after mirtazapine discontinuation, with subtherapeutic drug levels confirming withdrawal as the trigger 7.
Practical Clinical Approach
Before prescribing mirtazapine:
- Screen specifically for personal/family history of bipolar disorder, mania, or hypomania 1
- Assess for mixed depressive features (irritability, racing thoughts, decreased need for sleep)
- Review prior antidepressant responses, particularly any activation or mood destabilization
During treatment:
- Start at 7.5-15 mg if using primarily for sleep/appetite in patients with any bipolar risk factors
- Monitor closely in first 4-8 weeks for emergent manic symptoms
- If bipolar disorder is suspected or confirmed, combine with mood stabilizer (lithium or valproate preferred) 3
- Taper gradually rather than abruptly discontinue to minimize withdrawal-related mood destabilization 1
If mania emerges:
- Discontinue mirtazapine immediately
- Initiate or optimize mood stabilizer therapy
- Consider antipsychotic if symptoms are severe (haloperidol, olanzapine, risperidone per guidelines) 3
Important Caveats
The pediatric guideline notes that antidepressants (including SSRIs) may destabilize mood or incite manic episodes in youth, with caution that manic symptoms associated with antidepressants may represent unmasking of bipolar disorder rather than true drug-induced mania 9. This distinction has diagnostic implications per DSM criteria, which classify antidepressant-precipitated mania as "substance-induced" 9.
The absolute risk remains low in properly screened patients, but the consequences of missing bipolar disorder can be severe, including treatment resistance, rapid cycling, and increased suicide risk. The evidence supports that mirtazapine at low doses for insomnia carries minimal risk when mood stabilizers are on board, but antidepressant-dose monotherapy in unrecognized bipolar disorder poses meaningful risk 2.